SCHEMBL31166705

SCHEMBL31166705

Cc1noc(C)c1-c1cccc2sc(NC(=O)[C@H]3CCN(C#N)C3)nc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ UCHL1 P09936 4/20 0.49
▸ USP30 Q70CQ3 6/20 0.46
▸ ADORA2A P29274 1/20 0.46
▸ MEN1 O00255 4/20 0.44
▸ KMT2A Q03164 4/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ PSMD14 O00487 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ THRB P10828 1/20 0.44
▸ NPC1 O15118 3/20 0.43
▸ RAB9A P51151 3/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ MAPT P10636 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ CTDSP1 Q9GZU7 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ PARK7 Q99497 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27306151 1.00 UCHL1 (0.49) UCHL1USP30ADORA2AMEN1KMT2A
SCHEMBL27306156 0.88 UCHL1 (0.49) UCHL1USP30MEN1KMT2ARAB9A
SCHEMBL31166698 0.88 UCHL1 (0.49) UCHL1USP30MEN1KMT2ARAB9A
SCHEMBL27312174 0.88 UCHL1 (0.49) UCHL1USP30MEN1KMT2ARAB9A
SCHEMBL31166697 0.88 UCHL1 (0.49) UCHL1USP30MEN1KMT2ARAB9A
SCHEMBL17631728 0.84 ADORA2A (0.58) UCHL1USP30ADORA2AMEN1KMT2A
SCHEMBL17631725 0.84 ADORA2A (0.58) UCHL1USP30ADORA2AMEN1KMT2A
SCHEMBL30513241 0.83 UCHL1 (0.46) UCHL1USP30MEN1KMT2AKDM4E
SCHEMBL17631922 0.83 UCHL1 (0.46) UCHL1USP30MEN1KMT2AKDM4E
SCHEMBL17631792 0.82 UCHL1 (0.47) UCHL1USP30MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240335427-A1 SMALL MOLECULE INHIBITION OF DEUBIQUITINATING ENZYME JOSEPHIN DOMAIN CONTAINING 1 (JOSD1) AS A TARGETED THERAPY FOR LEUKEMIAS WITH MUTANT JANUS KINASE 2 (JAK2) DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-10-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240335427-A1 SMALL MOLECULE INHIBITION OF DEUBIQUITINATING ENZYME JOSEPHIN DOMAIN CONTAINING 1 (JOSD1) AS A TARGETED THERAPY FOR LEUKEMIAS WITH MUTANT JANUS KINASE 2 (JAK2) JAK1, JAK2, UBQLN1 UCHL1 148/4885USP30 12/4885ADORA2A 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback